期刊
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
卷 25, 期 4, 页码 298-302出版社
WILEY
DOI: 10.1002/hup.1117
关键词
delirium; risperidone; olanzapine; DRS-R-98; older age
资金
- Chonnam National University Hospital Research Institute of Clinical Medicine [CRI08019-1]
Objective This study compared the effectiveness of risperidone and olanzapine in the treatment of delirium. Methods This was a 7-day, randomized, comparative clinical trial of risperidone and olanzapine in patients with delirium. The primary outcome measure was the Delirium Rating Scale-Revised-98 (DRS-R-98). Results We enrolled 32 subjects (median age, 70 years). Significant within-group improvements in the DRS-R-98 scores over time were observed at every time point in both treatment groups; however, differences in the change of the DRS-R-98 score from baseline were not significant between the treatment groups. On the first day after drug treatment, there was a trend toward greater improvement in the DRS-R-98 score in the olanzapine group compared with the risperidone group, but it did not reach statistical significance (p = 0.076). The response rates did not differ significantly between the two groups (risperidone group: 64.7%, olanzapine group: 73.3%). However, the response to risperidone was significantly poorer in patients >= 70 years of age compared with those aged <70 years. There was no significant difference in the safety profiles, including extrapyramidal symptoms (EPSs), between the two groups. Conclusion Risperidone and olanzapine were equally effective in reducing delirium symptoms. The response to risperidone was poorer in the older age group. Copyright (C) 2010 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据